[Federal Register Volume 84, Number 226 (Friday, November 22, 2019)]
[Notices]
[Page 64563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-25404]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-538]


Importer of Controlled Substances Application: GE Healthcare

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before December 23, 2019. 
Such persons may also file a written request for a hearing on the 
application on or before December 23, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on July 15, 2019, GE Healthcare, 3350 North Ridge 
Avenue, Arlington Heights, Illinois 60004-1412 applied to be registered 
as an importer of the following basic class of controlled substance:

------------------------------------------------------------------------
          Controlled substance               Drug code       Schedule
------------------------------------------------------------------------
Cocaine.................................            9041              II
------------------------------------------------------------------------

    The company plans to import small quantities of Ioflupane, in the 
form of three separate analogues of cocaine, to validate production and 
quality control systems, for a reference standard, and for producing 
material for a future investigational new drug (IND) submission. 
Supplies of this particular controlled substance are not available in 
the form needed within the current domestic supply of the United 
States.

    Dated: November 7, 2019.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2019-25404 Filed 11-21-19; 8:45 am]
 BILLING CODE 4410-09-P